Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 1c; Reaffirms FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $1.59 -0.63%
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.18, $0.01 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $41.3 million versus the consensus estimate of $42.11 million.
Reaffirms FY12 outlook.
Reaffirms FY12 outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
- VivoPower Reports Unaudited First Quarter Fiscal Year 2027 Results with Revenue of US$6.8 Million, Net Profit of US$0.6 Million and Positive Operating Cash Flow of US$2.1 Million
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
